AR018917A1 - Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. - Google Patents

Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.

Info

Publication number
AR018917A1
AR018917A1 ARP990102993A ARP990102993A AR018917A1 AR 018917 A1 AR018917 A1 AR 018917A1 AR P990102993 A ARP990102993 A AR P990102993A AR P990102993 A ARP990102993 A AR P990102993A AR 018917 A1 AR018917 A1 AR 018917A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
alkyl
group
optionally substituted
adenosine
Prior art date
Application number
ARP990102993A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR018917A1 publication Critical patent/AR018917A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un compuesto de la formula (I) el cual es un agonista en el receptor de adenosina A1 de la formula (I) donde X representa O o CH2; R2 representa alquilo de1 a 3 átomos de carbono, alcoxi de 1 a 3 átomos de carbono, halogeno, hidrogeno; R3 representaH, fenilo (opcionalmente sustituido por halogeno), un grupoheteroarilo de 5 o 6 miembros, alcoxi de 1 a 6 átomos de carbono, alquilo1-6CO(CH2)n donde n es 0-6, cicloalquilo de 3 a 7 átomos de carbono, hidroxialquilo de1 a 6 átomos de carbono, halogeno o un grupo alquilo recto o ramificado, de 1 a 6 átomos de carbono, alquenilo de 1 a 6 átomos de carbono o alquinilo de 1 a 6átomos de carbono opcionalmente sustituido por uno o más halogenos; Y y Z representan O, N, CH, N(alquilo de 1 a 6 átomos decarbono) W representa CH, O, N, S,N(alquilo de 1 a 6 átomos de carbono) y en donde al menos uno de W y Z representa un heteroátomo (y cuando Y, Z y/o W es N, la presencia o ausencia de un Hadicional sería aparente para unapersona experta en la técnica) con la condicion que cuando W represente CH, Z represente N e Y represente O, R3 no puede serH; R4 y R5 representan independientemente H o un grupo alquilo C1-6, de cadena recta o ramificada; R1 representa H o un grupo seleccionado de:(1) -(alq)n-cicloalquilo C3-7, que incluye cicloalquilo puenteado, el grupo cicloalquilo opcionalmente sustituido por uno o más sustituyentes seleccionados de OH,halogeno,-alcoxi de 1 a 3 átomos de carbono, en donde (alq) representa alquileno de 1 a 3 átomos de carbono y n representa 0 o 1; (2) un grupo heterocíclico, alifáticode anillos de 4 a 6 miembros que contiene al menos un heteroátomo seleccionado de O, N, o S, opcionalmente sustituido por uno o más sustituyentes seleccionadosdel grupo que consistede -alquilo de 1 a 3 átomos de carbono, -CO2-alquilo de 1 a 4 átomos de carbono, -CO(alquilo de 1 a 3 átomos de carbono), -S(=O)n-(alquilo de 1 a 3 átomos de carbono), -CONRaRb (en donde Ra y Rb representan independientemente H o alquilo de 1 a 3 átomos de carbono) o =O; donde existe unátomo de azufre en el anillo heterocíclico, el azufre está opcionalmente sustituido por (=O)n, donde n es 1 o 2; alquilo de 1 a 12 átomos de carbono recto o
ARP990102993A 1998-06-23 1999-06-22 Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. AR018917A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9813554.4A GB9813554D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
AR018917A1 true AR018917A1 (es) 2001-12-12

Family

ID=10834247

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102993A AR018917A1 (es) 1998-06-23 1999-06-22 Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.

Country Status (40)

Country Link
US (2) US6492348B1 (es)
EP (2) EP1447407A1 (es)
JP (2) JP3378240B2 (es)
KR (1) KR100612797B1 (es)
CN (2) CN1202118C (es)
AP (1) AP2000002014A0 (es)
AR (1) AR018917A1 (es)
AT (1) ATE277941T1 (es)
AU (1) AU758018B2 (es)
BG (1) BG65064B1 (es)
BR (1) BR9911498A (es)
CA (1) CA2335520C (es)
CO (1) CO5040216A1 (es)
DE (1) DE69920697T2 (es)
EA (1) EA003828B1 (es)
EE (1) EE04853B1 (es)
ES (1) ES2226399T3 (es)
GB (1) GB9813554D0 (es)
GE (1) GEP20032958B (es)
HK (1) HK1034978A1 (es)
HR (1) HRP20000896B1 (es)
HU (1) HUP0102453A3 (es)
ID (1) ID27484A (es)
IL (2) IL140284A0 (es)
IS (1) IS5773A (es)
MY (1) MY122481A (es)
NO (1) NO318788B1 (es)
NZ (1) NZ508915A (es)
OA (1) OA11574A (es)
PE (1) PE20000704A1 (es)
PL (1) PL194087B1 (es)
PT (1) PT1090019E (es)
RS (1) RS50042B (es)
SI (1) SI1090019T1 (es)
SK (1) SK19582000A3 (es)
TR (1) TR200100449T2 (es)
TW (1) TW541312B (es)
UA (1) UA64794C2 (es)
WO (1) WO1999067262A1 (es)
ZA (1) ZA200007514B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
WO2001064202A2 (en) * 2000-03-01 2001-09-07 Euro-Celtique S.A. Tramadol for the treatment of functional gastrointestinal disorders
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0115182D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Medicaments
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7144871B2 (en) * 2002-02-19 2006-12-05 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
WO2003106475A2 (en) * 2002-06-17 2003-12-24 Glaxo Group Limited Process
AU2003263846B2 (en) * 2002-08-15 2009-12-17 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
WO2004055033A1 (en) * 2002-12-18 2004-07-01 Glaxo Group Limited Adenosine derivative in polymorph iv form
WO2004055034A1 (en) * 2002-12-18 2004-07-01 Glaxo Group Limited Polymorph
WO2004055032A1 (en) * 2002-12-18 2004-07-01 Glaxo Group Limited Adenosine derivative in polymorph v form
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
WO2005053712A1 (en) * 2003-12-02 2005-06-16 Glaxo Group Limited Use of adenonsine derivatives for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, niddm
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) * 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CN101712709A (zh) 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
EP2849566B1 (en) * 2012-02-11 2018-04-04 Academia Sinica Adenosine analogues for the treatment of pain
KR20170119705A (ko) * 2015-02-24 2017-10-27 화이자 인코포레이티드 항암제로서 유용한 치환된 뉴클레오시드 유도체
CN108864099A (zh) * 2018-09-08 2018-11-23 湖北荆洪生物科技股份有限公司 一种高纯6-糠氨基嘌呤的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
DK62592D0 (es) * 1992-05-14 1992-05-14 Novo Nordisk As
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1995003304A1 (en) * 1993-07-23 1995-02-02 Merrell Pharmaceuticals Inc. Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
WO1998001459A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HUP0102453A3 (en) 2002-10-28
AP2000002014A0 (en) 2000-12-31
OA11574A (en) 2004-07-21
KR20010083067A (ko) 2001-08-31
JP2002518509A (ja) 2002-06-25
JP2003040891A (ja) 2003-02-13
US20030096788A1 (en) 2003-05-22
NZ508915A (en) 2003-09-26
EA003828B1 (ru) 2003-10-30
HRP20000896B1 (en) 2006-03-31
HRP20000896A2 (en) 2001-12-31
CA2335520C (en) 2007-02-20
EP1447407A1 (en) 2004-08-18
CN1616459A (zh) 2005-05-18
IS5773A (is) 2000-12-15
KR100612797B1 (ko) 2006-08-17
DE69920697T2 (de) 2005-02-24
NO20006520L (no) 2001-02-14
IL140284A0 (en) 2002-02-10
US6677316B2 (en) 2004-01-13
US6492348B1 (en) 2002-12-10
BG105155A (en) 2001-09-28
SK19582000A3 (sk) 2001-11-06
NO318788B1 (no) 2005-05-09
ID27484A (id) 2001-04-12
AU4514699A (en) 2000-01-10
HK1034978A1 (en) 2001-11-09
BG65064B1 (bg) 2007-01-31
JP3378240B2 (ja) 2003-02-17
EA200001222A1 (ru) 2001-08-27
RS50042B (sr) 2008-11-28
TR200100449T2 (tr) 2001-08-21
PE20000704A1 (es) 2000-08-03
HUP0102453A2 (hu) 2002-04-29
YU82800A (sh) 2003-04-30
IL140284A (en) 2006-04-10
NO20006520D0 (no) 2000-12-20
CN1314910A (zh) 2001-09-26
PL345089A1 (en) 2001-12-03
TW541312B (en) 2003-07-11
GEP20032958B (en) 2003-04-25
MY122481A (en) 2006-04-29
ATE277941T1 (de) 2004-10-15
CO5040216A1 (es) 2001-05-29
DE69920697D1 (de) 2004-11-04
EP1090019B1 (en) 2004-09-29
PL194087B1 (pl) 2007-04-30
AU758018B2 (en) 2003-03-13
EP1090019A1 (en) 2001-04-11
BR9911498A (pt) 2001-03-20
PT1090019E (pt) 2005-01-31
ZA200007514B (en) 2002-01-23
EE200000784A (et) 2002-04-15
CA2335520A1 (en) 1999-12-29
ES2226399T3 (es) 2005-03-16
SI1090019T1 (en) 2005-02-28
GB9813554D0 (en) 1998-08-19
UA64794C2 (en) 2004-03-15
WO1999067262A1 (en) 1999-12-29
EE04853B1 (et) 2007-06-15
CN1202118C (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
AR018917A1 (es) Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.
AR011229A1 (es) Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
ECSP034611A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina
ES2121441T3 (es) Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
DK0628311T3 (da) Xanthinderivater som antidepressive midler
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
AR011913A1 (es) Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
AR247213A1 (es) Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos.
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
ATE173459T1 (de) Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien
MX9602979A (es) Compuestos heterociclicos terapeuticos.
DK71780A (da) Fremgangsmaade til fremstilling af difenylhydantoinderivater
PT1064281E (pt) Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais
AR246962A1 (es) Procedimiento para preparar derivados alquilamino-alquilenicos de ciertos 2h-1-benzopiranos.
CS621987A2 (en) Coating composition
FI894061A (fi) Menetelmä lääkeaineina käyttökelpoisten , -disubstituoitujen N-sykloalkyylialkyylibentsyyliamiinien valmistamiseksi ja niiden synteesivälituotteita
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
MX9301045A (es) Procedimiento para preparar antagonistas receptores de fibrinogeno.
ES552572A0 (es) Un procedimiento para la preparacion de derivados de beta-lactama.
PT89643A (pt) Processo para a preparacao de derivados de 2-{(4-piperidinil)-metil}-1,2,3,4-tetrahidro-isoquinoleina e de composicoes farmaceuticas que os contem
SE8504346D0 (sv) N-alkyl(en)-n-(o,o-disubstituerad tiofosforyl)-n',n'-disubstituerade glycinamider, sett att framstella dessa samt akaricid, insekticid och fungicid, innehallande dess foreningar som verksam bestandsdel

Legal Events

Date Code Title Description
FB Suspension of granting procedure